House Republicans are considering nixing a Medicaid drug-pricing plan floated by President Trump and fiercely opposed by ...

Tempus AI is gaining traction and on track for profits this year; high short interest and rising institutional activity point ...

CompanyOverview|NASDAQ:TEM] Tempus AI (NASDAQ: TEM) is an interesting AI story that operates a platform and library for ...

We recently published a list of Why These 10 Stocks Soared Today. In this article, we are going to take a look at where ...

Nancy Pelosi's newest stock bet, Tempus AI, remains an enticing buy following a promising Q1 2025 earnings report.

The biggest strategic highlight for Tempus AI Inc. (NASDAQ: TEM) during the first quarter was a multi-million dollar deal to build "the world's largest foundation model for oncology." ...

Learn about April 2025’s top biotech deals, featuring major collaborations in bispecific antibodies, protein therapies, and ...

The firm's Genomics revenues increased 89 percent, while Data and Services revenues rose 43 percent year over year.

Lefkofsky announced a three-year, $200 million data and modeling license agreement with AstraZeneca and Pathos to build the world’s largest foundation model in oncology. This agreement increased ...

Tempus AI continued to see dramatic revenue and gross profit growth in the first quarter, with year-over-year revenue up 75.4 ...

Tempus AI reports first-quarter revenue of $255.74 million, beating estimates of $248.13 million. The AI-focused precision ...

Pathos AI has launched a $400 million funding round and already raised nearly $283 million. The Chicago-based startup formed ...